FindTrial
Sign In

Based on the expression of ‘TH1/TH2 cell imbalance’ and ‘epithelial-interstitial transformation’ related proteins, explore the mechanism of ‘Xiaoyu Sanjie Decoction’ in the treatment of plasma cell mastitis

Based on the expression of ‘TH1/TH2 cell imbalance’ and ‘epithelial-interstitial transformation’ related proteins, explore the mechanism of ‘Xiaoyu Sanjie Decoction’ in the treatment of plasma cell mastitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027591
Enrollment
Unknown
Registered
2019-11-20
Start date
2019-12-02
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plasma cell mastitis

Interventions

plasma cell mastitis group:immunohistochemistry
Mammary fibroids group:immunohistochemistry
adenosis of breast group:immunohistochemistry

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
28 Years to 45 Years

Inclusion criteria

Inclusion criteria: All the cases from the Chinese Academy of Traditional Chinese Medicine Xiyuan Hospital, all cases have been confirmed by the pathology department of our hospital as: plasma cell mastitis case (20 cases), Mammary fibroids (20 cases),adenosis of breast(20 cases), the patients are female, aged 28-45 years old, non-lactation period. The specimen is obtained by surgical removal and puncture biopsy.

Exclusion criteria

Exclusion criteria: 1. Pathologically confirmed that the tissue contains tuberculosis and malignant tumor cells; 2. Pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
IFN-gama;IL-4;E-Cadherin;P-120;Vimentin;TGF-beta 1;—

Countries

China

Contacts

Public ContactLi Zheng

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

zhengl64@163.com+86 010-62835241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026